TUKYSA

Procedural steps taken and scientific information after the authorisation

Application number	Scope	Opinion/ Notification[1] issued on	Commission Decision Issued[2] / amended on	Product Information affected[3]	Summary
N/0018	Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)	02/04/2024		PL	
PSUSA/10918 /202304	Periodic Safety Update EU Single assessment - tucatinib	30/11/2023	n/a		PRAC Recommendation - maintenance

[1] Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.
[2] A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.
[3] SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

IB/0016/G	This was an application for a group of variations. B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS B.I.a.3.a - Change in batch size (including batch size ranges) of AS or intermediate - Up to 10-fold increase compared to the originally approved batch size	09/10/2023	n/a		
IA/0015/G	This was an application for a group of variations. B.II.c.3.z - Change in source of an excipient or reagent with TSE risk - Other variation B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure	12/09/2023	n/a		
II/0013	Update of section 5.1 of the SmPC to reflect updated efficacy results from study ONT-380-206 (HER2CLIMB), listed as a PAES in the Annex II of the Product Information. This is a phase 2 randomized, double-blinded, controlled study of tucatinib vs. placebo in combination with capecitabine and trastuzumab in patients with pretreated unresectable locally advanced or metastatic HER2+ breast carcinoma. The Annex II is updated accordingly. C.I.11.b - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of	20/07/2023		SmPC and Annex II	As planned per protocol, approximately two years after last patient randomized, the final OS analysis was performed based on 370 events, which corresponded to a median follow-up of 29.6 months. Median OS was 24.7 months (95% CI: 21.6, 28.9) for patients on the tucatinib + trastuzumab + capecitabine arm compared to 19.2 months (95% CI: 16.4, 21.4) for patients on the placebo + trastuzumab + capecitabine arm (HR = 0.725; 95% CI: 0.585, 0.898). For more information, please refer to the Summary of Product Characteristics.

	change(s) which require to be further substantiated by new additional data to be submitted by the MAH where significant assessment is required				
PSUSA/10918 /202210	Periodic Safety Update EU Single assessment - tucatinib	12/05/2023	n/a		PRAC Recommendation - maintenance
IB/0012/G	This was an application for a group of variations. B.II.b.3.z - Change in the manufacturing process of the finished or intermediate product - Other variation B.II.e.2.z - Change in the specification parameters and/or limits of the immediate packaging of the finished product - Other variation B.II.d.z - Change in control of the Finished Product - Other variation B.II.e.7.a - Change in supplier of packaging components or devices (when mentioned in the dossier) - Deletion of a supplier	30/03/2023	n/a		
II/0010	Submission of the final report from study SGNTUC-017 (MOUNTAINEER) listed as a category 3 study in the RMP. This is a Phase 2, open label study of tucatinib combined with trastuzumab in patients with HER2+ metastatic colorectal cancer. Primary objective is to determine the antitumor activity of tucatinib given in combination with trastuzumab. The RMP version 1.1 is approved. C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission	16/03/2023	n/a		Not applicable

	of studies to the competent authority				
PSUSA/10918 /202204	Periodic Safety Update EU Single assessment - tucatinib	15/12/2022	24/02/2023	SmPC and PL	Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/10918/202204.
IB/0009/G	This was an application for a group of variations. B.I.a.1.a - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The proposed manufacturer is part of the same pharmaceutical group as the currently approved manufacturer B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation B.I.b.2.e - Change in test procedure for AS or	07/02/2023	n/a		

	starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate				
IAIN/0008/G	This was an application for a group of variations. B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site B.II.b.1.b - Replacement or addition of a manufacturing site for the FP - Primary packaging site	09/09/2022	n/a		
PSUSA/10918 /202110	Periodic Safety Update EU Single assessment - tucatinib	10/06/2022	n/a		PRAC Recommendation - maintenance
N/0006	Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)	11/02/2022	02/06/2022	PL	
IB/0004	B.II.b.3.z - Change in the manufacturing process of the finished or intermediate product - Other variation	09/12/2021	n/a		
PSUSA/10918 /202104	Periodic Safety Update EU Single assessment - tucatinib	28/10/2021	n/a		PRAC Recommendation - maintenance
IAIN/0002/G	This was an application for a group of variations. B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS	15/04/2021	02/06/2022	SmPC, Annex II, Labelling and PL	

	A.5.a - Administrative change - Change in the name and/or address of a manufacturer/importer responsible for batch release B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.I.a.3.a - Change in batch size (including batch size ranges) of AS or intermediate - Up to 10-fold increase compared to the originally approved batch size A.1 - Administrative change - Change in the name and/or address of the MAH B.II.b.4.a - Change in the batch size (including batch size ranges) of the finished product - Up to 10-fold compared to the originally approved batch size				
IB/0001	B.I.b.2.z - Change in test procedure for AS or starting material/reagent/intermediate - Other variation	11/03/2021	n/a		